Evidence map›Paper›PMID 33846043›Full record

ArticleVaccine2021

Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.

Sophia Hatziantoniou, Helena C Maltezou, Athanasios Tsakris, Gregory A Poland, Cleo Anastassopoulou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Review
  16. Article
  17. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sophia HatziantoniouLaboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece.
Helena C MaltezouDirectorate of Research, Studies and Documentation, National Public Health Organization, Athens, Greece.
Athanasios TsakrisDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Gregory A PolandMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
Cleo AnastassopoulouDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: cleoa@med.uoa.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnaphylaxisCOVID-19COVID-19 VaccinesHumansRNA, MessengerSARS-CoV-2COVID-19 VaccinesRNA, MessengerAllergyAnaphylaxisBNT162b2COVID-19ExcipientsHypersensitivityLipid nanoparticles (LNPs)Polyethylene glycol (PEG)SARS-CoV-2Spike

Identifiers

PMID33846043
PMCPMC8023205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.